Efficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases
| Autor: | Ali Kaya, M. Ali Kaplan, Senar Ebinç, İrem Yasin, Zeynep Oruç, Ali Murat Tatli, Özlem Nuray Sever, Abdullah Sakin, Esra Zeynelgil, Serkan Menekse, Neslihan Özyurt, Nazim Serdar Turhal, Mustafa Karaagac, Abdurrahman Isikdogan, Sinan Koca, Engin Kut |
|---|---|
| Přispěvatelé: | Dicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Tıbbi Onkoloji Ana Bilim Dalı, Oruç, Zeynep, Kaplan, M. Ali, Ebinç, Senar, Işıkdoğan, Abdurrahman, Tıp Fakültesi |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty 030232 urology & nephrology Docetaxel Gastroenterology Drug Administration Schedule Hormone-Refractory Disease 03 medical and health sciences Prostate cancer chemistry.chemical_compound 0302 clinical medicine Internal medicine Hormone-refractory disease Nitriles Phenylthiohydantoin Humans Medicine Enzalutamide Visceral metastasis Aged Retrospective Studies Aged 80 and over business.industry Prostate Cancer Significant difference Treatment options General Medicine Visceral Metastasis Middle Aged medicine.disease Hormone refractory prostate cancer Progression-Free Survival Prostatic Neoplasms Castration-Resistant Oncology Tolerability chemistry 030220 oncology & carcinogenesis Benzamides Androstenes business Median survival medicine.drug |
| Popis: | WOS:000621799100001 PMID: 33631986 Aim: To assess the efficacy and tolerability of the first-line treatment options for hormone-refractory prostate cancer patients with visceral metastases. Materials and methods: The records of 191 patients diagnosed with hormone-refractory prostate cancer with visceral metastases were analyzed retrospectively. Results: Docetaxel was administered to 61.2% (n = 117), abiraterone to 14.2% (n = 27) and enzalutamide to 9.4% (n = 18) as the first-line treatment. The median survival of the patients receiving docetaxel, abiraterone and enzalutamide as the first-line treatment during the hormone-refractory period was 15 (95% Cl: 12.9-17) months, 6 (95% Cl: 1.8-10.1) months and 11 (95% Cl: 0.9-23.1) months (p = 0.038), respectively. Conclusion: The present study established a statistically significant difference in favor of docetaxel in terms of overall survival and progression-free survival. Lay abstract The optimal therapeutic option for castration-resistant prostate cancer (CRPC) patients with visceral metastases is unknown. We assessed the efficacy and tolerability of the first-line treatment options for CRPC patients with visceral metastasis. One hundred ninety-one patients diagnosed with CRPC with visceral metastases were included in the study. The present study established a statistically significant difference in favor of docetaxel in terms of overall survival and progression-free survival between first-line docetaxel, abiraterone and enzalutamide treatments in CRPC patients with visceral metastases. For patients who cannot undergo chemotherapy, enzalutamide, among novel androgen pathway inhibitors, may be the most appropriate option, given its numerical, although statistically insignificant, difference in overall survival and its fewer side effects compared with abiraterone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|